IL17A and uveitis: - The choice of first-line biological treatment in axial forms (anti-TNF or anti-IL17, generally anti-TNF) must take into account the presence or absence of uveitis or Inflammatory bowel disease (IBD), patient’s profile, and the decision must be shared between the patient and the physician.